Pulmonary support for people with myotonic dystrophy during COVID-19 pandemic

Le français suit

 

New COVID-19-related guidance has been produced for people living with myotonic dystrophy who already use some respiratory support at home or who need it if they get sick. These devices are very important to keep you breathing well, but extra care needs to be taken to make sure they are kept clean and to limit the spread of the virus, as they can increase the risk of virus-infected particles being released into the air.

Many people with myotonic dystrophy do not use ventilation when they are otherwise healthy, but some do use non-invasive ventilation at home. Others may require respiratory support if they contract COVID-19 because their breathing muscles are weaker than normal.

Specific guidelines for myotonic dystrophy patients and their doctors in case of a COVID-19 infection, created by Myotonic and the CHEST Home-Based Mechanical Ventilation and Neuromuscular Disease NetWork, can be downloaded HERE.

You can share these recommendations with your care providers and with any medical providers you have to see. Let them know you have myotonic dystrophy and that these guidelines were developed by leading pulmonologists and neurologists specifically for myotonic dystrophy patients suspected of being infected with COVID-19.

If you use respiratory support at home but are currently healthy, see additional guidance about how to avoid exposure to the coronavirus HERE.

 

***

 

 

 

 

De nouveaux conseils liés à la COVID-19 sont disponibles pour les personnes vivant avec la dystrophie myotonique qui utilisent déjà une aide respiratoire à domicile ou qui en ont besoin si elles tombent malades. Ces appareils sont très importants pour vous permettre de bien respirer, mais il faut veiller à ce qu’ils restent propres et à limiter la propagation du virus, car ils peuvent augmenter le risque de libération de particules infectées par le virus dans l’air.

De nombreuses personnes atteintes de dystrophie myotonique n’utilisent pas de ventilation lorsqu’elles sont en bonne santé, mais certaines utilisent une ventilation non invasive à domicile. D’autres peuvent avoir besoin d’une assistance respiratoire si elles contractent la COVID-19 parce que leurs muscles respiratoires sont plus faibles que la normale.

Les directives spécifiques pour les patients atteints de dystrophie myotonique et leurs médecins en cas d’infection par COVID-19, crées par Myotonic et traduites par NMD4C, peuvent être téléchargées ICI.

Vous pouvez partager ces recommandations avec vos professionnels de la santé et avec tous les intervenants médicaux que vous devez consulter. Faites-leur savoir que vous êtes atteint de dystrophie myotonique et que ces recommandations ont été élaborées par des pneumologues et des neurologues de renom, spécifiquement pour les patients atteints de dystrophie myotonique soupçonnés d’être infectés par COVID-19.

Si vous utilisez une assistance respiratoire à domicile mais que vous êtes actuellement en bonne santé, consultez les conseils supplémentaires sur la manière d’éviter l’exposition au coronavirus ICI.

 

lungs

Read next...

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.

Website - SBMA published on CMAJ.png

New Best Practice Recommendations for SBMA Care in Canada

Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!

2025 NMD4C ANNUAL MEETING

Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting

On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.

2025 Clinical Summer School

NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders

On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.

2026 Neuromuscular Postdoc Research Fellowship Competition

2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!

Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)

Clinical Fellowship Awardees

Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients

We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.